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Enterovirus associated hand, foot and mouth disease continues to be a prominent public 
health issue despite the numerous vaccine trials and drug development attempts. The lack 
of a specific and protective antiviral drug has made disease management extremely 
challenging and gravely underscores the need for effective therapy options. Nelfinavir, 
belonging to the HIV-1 protease inhibitors, was found to have significant antiviral 
activity compared to other HIV-1 protease inhibitors. With a low cytotoxicity and high 
inhibitory action against both the BrCr and H strain of EV71, nelfinavir exhibited 
potential broad spectrum antiviral properties. Additionally, its ability to impede the virus 
irrespective of the stage of the infection makes it a more promising therapeutic option. 
The data strongly support the potential usefulness of nelfinavir as a broad spectrum 
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Hand, Foot and Mouth Disease & Enterovirus 71 
Even after almost five decades since its discovery in 1969, hand, foot and mouth disease 
(HFMD) caused by Enterovirus 71 (EV71), continues to be a major global public health 
concern. Although the first case was identified in the United States, the incidence of the 
disease was later recorded to be predominant across the Asia-Pacific region at epidemic 
scales [1]. In a span of 4 years, 7.2 million probable cases and 267,942 deaths were 
reported in China alone [2]. Other countries that have been swept by the HFMD epidemic 
are Taiwan, Japan, Thailand, Singapore and Vietnam [3,4,5,6,7]. It is mainly a pediatric 
infection that is most common in children under 5 years of age, however, cases of 
infection in adults have also been recorded [8]. 
The disease is usually mild, self-limiting in nature and is resolved quickly in healthy 
children with a robust immune system. In a few cases where the infection is not cleared, 
children develop symptoms as the disease progresses. At the end of the incubation period, 
children present with fever and a papulovesicular rash on their palms, soles and in the 
oral cavity. In a lot of cases, the rash is accompanied by herpangina or painful sores and 
ulcers on the tongue and palette and upper respiratory tract infection [9]. For instance, in 
their three and half year long study in Malaysia, Mong How Ooi and co workers studied 
725 children with HFMD, and noted 48% (169/333) of the patients who had skin vesicles 
positive for HFDM. The study further suggested that the use of throat swabs in addition 
to skin vesicle swabs increased the diagnostic value for HFMD (67% virus identification) 
[10]. Similarly in another study, Umesh Parashar and colleagues observed that 83% of 
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the 29 cases had either vesicular rashes or oral ulcers [11]. In the absence of supportive 
care, the infection spreads systemically and results in severe neurological sequelae, such 
as aseptic meningitis, encephalitis and flaccid paralysis [9]. The complications are a 
major challenge not only in terms of clinical management but also for diagnosis as they 
are common to a wide range of viral infections, including measles, rubella, mumps and 
adenoviruses [9]. This can cause incorrect diagnosis and subsequent initiation of therapy 
to resolve the symptoms. For instance, poor differentiation of HFMD from measles or 
adenovirus infection may result in unnecessary initiation of post exposure prophylaxis 
(Vitamin A treatment or passive immunization depending on the time of measles 
exposure or Cidofovir in rare cases of adenovirus infection). This delay in turn would 
result in a poor prognosis [12, 13].  
Throat, ulcer and rectal swabs, vesicular fluid, CSF, serum and urine are usually collected 
for virus isolation and confirmation. Laboratory identification is done through cell culture 
using rhabdomyosarcoma cells, African green monkey kidney cells or human lung 
fibroblast cells. Serology and more recently molecular serotyping using PCR are being 
performed for a more definitive diagnosis [9].  
In terms of prevention, although there is no licensed vaccine available for EV71 
infection, fortunately there are several candidate vaccines that are in the pipeline.  For 
instance, Feng-Cai and colleagues have reported 90% vaccine efficacy against EV71-
associated HFMD and 80.4% efficacy against EV71 associated disease in the phase three 
clinical trials of their vaccine candidate [14]. While these advances are a step forward in 
the fight against HFMD caused by EV71, this strategy would not be applicable to all 
HFMD cases. This is because, in addition to EV71, HFMD has been shown to be widely 
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associated with coxsackie A16 virus (CA16). In a clinical survey conducted by Fan 
Yang's group across China in 2009, 50.4% of the 266 HFMD cases were identified as 
EV71 associated cases and 38.3% were CA16 cases [15]. Thus a lot of work is still 
required on the disease management front. Currently, there is no approved treatment 
regimen or drug for HFMD [16]. Trials by different scientific groups have been 
conducted in the past to test the antiviral properties of many compounds like Pleconaril, 
Ribavarin, Rupintrivir etc [17,18]. However, none of them were effective enough to 
warrant licensure and were subsequently terminated. As a result of this, disease 
management has been primarily dependent on patient care and temporary alleviation of 
symptoms.  Thus, the lack of a specific antiviral drug for treatment of HFMD continues 
to be a major handicap for clinicians and public health workers globally and underscores 
the dire need for developing effective drugs rapidly. 
Traditionally, drug discovery has been a labor, time and cost intensive endeavor and in 
many cases fails to create an immediate and much needed impact on an infection. Thus, 
new methods of drug discovery have been developed in recent times and one such 
approach is drug repositioning [19]. This involves testing of well established drugs as 
possible candidates for new infections. One such class of drugs is the protease inhibitors. 
HIV-1 protease inhibitors have been in wide use for treatment of HIV-1 infected patients. 
Currently there are nine FDA approved HIV-1 protease inhibitors available namely 
Saquinavir, Ritonavir, Lopinavir, Indinavir, Nelfinavir, Atazanavir, Amprenavir, 
Darunavir & Tipranavir which are used in various HAART regimens [20]. These drugs 
are potent inhibitors of the HIV-1 protease enzyme that is essential for processing the 
viral polyprotein and maturation of viral particles [21]. Specifically targeting this enzyme 
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hinders the cleavage of the polyprotein which ultimately leads to the formation of non- 
infectious virions. Through various clinical trials, population and cohort studies, these 
drugs have been shown to be effective in reducing the viral load and increasing the CD4 
T cell counts of HIV-1 infected patients. Hence they are effectively able to slow down the 
progression of the infection to the AIDS phase [22]. Also numerous biosafety and 
toxicity studies were conducted to validate drug safety and tolerance. These data thus 
provide ample evidence of their antiviral capacity and establish them as safe, validated 
and well documented drug candidates for repositioning.  
Additionally, in 2009 Toma, S and colleagues, reported the inhibitory activity of 
Nelfinavir on the intracellular replication of Hepatitis C virus. They noted that the 
inhibitory effect was seen at low doses and that the drug failed to cause cytotoxicity and 
apoptosis [23]. In 2003, Chen, XP and co-workers, observed the lack of Severe Acute 
Respiratory Syndrome (SARS) in 19 AIDS patients hospitalized during the SARS 
epidemic [24]. Similar peculiar findings were also reported in the same year by Chan, 
KS's group in Hong Kong where SARS patients treated with HIV-1 protease inhibitors 
showed better clinical outcome than those who were not [25].  Based on these 
observations, Chen, XP's group proposed the possible use of HAART for the treatment 
and prevention of SARS [26]. Thus, these studies provide additional evidence that HIV-1 
PIs can have potential broad spectrum anti-viral effects. 
In light of the above mentioned findings, we investigated the possible use of HIV-1 







1. Enterovirus 71  
1.1 Molecular Epidemiology 
As the name suggests, EV71 belongs to the genus enterovirus of the picornaviridae 
family of viruses which has human rhinoviruses, coxsackie viruses, poliovirus and 
hepatitis A virus as prominent members. Phylogenetic analysis of the EV71 revealed 
15% divergence within the group and was used to classify EV71 into three distinct 
groups, A, B and C (Figure.1). After the 2 prominent EV71 epidemics in Bulgaria and 
Hungary, most of the epidemics were reported from the Asia Pacific region that included 
Australia and Japan. It was noted that most of the epidemics in these regions were caused 
by the group B and C strains of EV71. With improved surveillance in eastern countries, it 
was found that while group B viruses of EV71 were dominant in Singapore and 
Malaysia, the group C viruses were mostly circulating in mainland China and Vietnam 
[8]. Molecular typing of the isolates led to further classification of the viruses within the 
groups.  
1.2 Structure and genome  
EV71 is a non-enveloped virus containing a 7.4 Kb positive sense, single stranded RNA 
genome in a capsid composed of four structural proteins, VP1, VP2, VP3 and VP4. There 
are 60 identical subunits of each protein arranged such that they form a regular 
icosahedron. Thus, the capsid has five fold axes where 5 VP1 subunits interact, three fold 
axes where VP1-3 subunits interact and two fold axes where any two of three proteins 
interact [8,27]. A characteristic picornavirus feature exhibited by EV71 is its 
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triangulation number (T). Contrary to the theoretically probable particle triangulation 
number (T)=1, EV71 has a pseudo T=3 arrangement. This is because despite having 
similar conformations, geometrically these proteins appear to be separate repeating 
subunits present in a T=3 arrangement. Hence they are said to have a pseudo T= 3 
arrangement [27]. Additionally, VP4 is present on the inside tethering the genome to the 
capsid [8] (Figure.2). Various studies have suggested that the capsid has depressions or 
canyons near its fivefold vertex and these may be involved in attachment to receptors on 
host cells [28,29]. To date five host cell receptors associated with EV71 binding have 
been identified: (i) the scavenger receptor B (SCARB2) which is expressed ubiquitously 
[30], (ii) human P-selectin glycoprotein ligand-1 (PSGL-1) that is expressed mainly on 
white blood cells [31], (iii) sialyated glycans found in the gastrointestinal and respiratory 
tracts [32], (iv) annexin II expressed on human nasopharyngeal mucosa, fetal human 
brain cells [33] and more recently (v) heparin sulfate that is expressed by all cell types 
[34]. This widespread expression of most of these receptors may account for the systemic 
nature of EV71 infection.  
1.3 Viral Replication and protein synthesis 
Once the viral particle is attached to a host through the binding receptors, the mature 
virus undergoes a conformational change that transforms it into an intermediate form 
exhibiting altered antigenic characteristics [28]. This triggers the release of the RNA 
genome into the host cell cytoplasm via the two fold axis of the icosahedron capsid. It 
should be noted here that the viral RNA genome is polyadenylated at the 3' end and has a 
small protein, Vpg linked to its uncapped 5' end. Following its entry into the cytoplasm, 
the RNA genome is readily translated into a single polyprotein with the aid of the internal 
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ribosome entry site (IRES) that is located in the 5' UTR of the RNA. In addition to the 
IRES that enables the RNA translation to occur in a cap-independent manner, host cell 
factors like IRES-specific transacting factors (ITAFs) are recruited to translate the E71 
open reading frame [35]. The polyprotein thus formed undergoes cleavage by viral 
protease 3C and 2A to yield the 11 structural and non structural proteins which in turn 
facilitate viral replication. 3D, the viral RNA dependent RNA polymerase, is used to read 
the RNA genome and replication occurs in a vesicle membrane structure. The structural 
proteins assemble to form the procapsid and packaging of the RNA genome into the 
empty capsid results in the formation of an infectious mature virion which then lyse the 
cell to exit [8] (Figure.3). 
1.4 Pathogenesis 
The primary route of transmission of EV71 is through the oro-fecal route. However, in a 
lot of cases, infection can be caused by vesicular fluids, respiratory droplets and oral 
secretions [9]. Once ingested, typically, virus colonization and replication is restricted to 
the Peyer's patches, tonsils and to a lesser extent in the local lymph nodes and is thus 
indicative of the asymptomatic phase of the infection. Overcoming this restraint results in 
dissemination of the virus to other organs such as the liver, heart, lungs, spleen and the 
central nervous system, thus marking the start of the symptomatic phase [8].  
However, at the molecular level, not much is known about the pathogenesis of EV71 
infection. Data from the in vitro studies conducted by Lei and colleagues reported a 
significant decrease in IFN production by EV71 infected HeLa and RD cells [37]. They 
showed that the 3C protease, through its association with RIG-I and IPS-1, disrupted the 
nuclear translocation and subsequent activation of the IRF3 and ultimately down 
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regulated the production of type 1 IFN in the host cell. In 2011, Lei et al further proposed 
impairment of TRIF adaptor protein as a second mechanism for 3C protease mediated 
suppression of IFN production [36]. Interestingly, in their recently published study, 
Chuanzhen Chi and colleagues observed high levels of IFN-β induction using human 
colorectal adenocarcinoma cells (HT-29) [37]. Additionally, they also recorded a 45-fold 
increase in the expression of IL-6 and significant increase in secretion of chemokines like 
IP10 and CCL5. Cell death through apoptosis is also another mechanism employed by the 
host immune system to control the spread of infection. Chuanzhen Chi's group found not 
only an upregulated expression of FasL which can further activate caspase 6 and 7 
downstream, but also the activation of caspase 9, indicative of mitochondrial-mediated 
apoptosis of EV71 infected epithelial cells [37,38]. While these and the aforementioned 
data are proof of the existence of immune components that are in place to control 
infection, in a few cases, they are easily overcome by the virus and result in the 
development of a systemic infection with severe sequelae. 
1.4.1 Damage to central nervous system 
As in the case of other enterovirus infections, severe EV71 infection patients present with 
aseptic meningitis, flaccid paralysis and encephalitis, demonstrating the extreme damage 
it causes to the central nervous system [8]. Several mouse studies and post mortem 
examinations of fatal human cases implicate retrograde axonal spread of the virus 
through the peripheral and cranial nerves [39]. Histological examination of tissue 
biopsies highlights the presence of parenchymal inflammation and perivascular cuffing 
[8]. Post mortem MRI of EV71 infected children with brainstem encephalitis showed 
widespread inflammation of the grey matter in the spinal cord and major parts of the 
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medulla oblongata. Additionally studies have also illustrated the association between 
EV71 infection, neurological sequelae and cognitive dysfunction [8]. In their study, 
Chang LN and colleagues found that patients with EV71 infection were more prone to 
neurological sequelae due to viral invasion and damage of neurons. They also observed 
that EV71 infected children displayed impaired cognitive functions [40]. However, a 
direct causal relationship between the two is yet to be determined.    
1.4.2 Severe pulmonary edema & Cardiac failure 
EV71 has also been shown to be associated with fulminant pulmonary edema. However, 
whether this is the cause or effect of CNS inflammation remains unclear [8]. Some 
researchers have suggested that the elevated levels of cytokines such as IL-1ß, IL-6, IL-
10, IFN-γ and TNF-α noticed in EV71 infection may contribute to the increased vascular 
permeability, which in turn causes pulmonary edema. Apart from this, studies have 
reported pediatric cases with weakened cardiac function [41]. While the data is not 
sufficient due to the lack of appropriate animal models to study the pathogenesis of the 
virus, it does highlight the possible connections between EV71 infection and the chronic 
sequelae observed in patients. 
1.5 Vaccines 
The successes of the poliovirus and hepatitis A vaccine have ironically been difficult to 
replicate for EV71. This could be attributed to the non availability of a good animal 
model to study EV71 pathogenesis. Another concern is the insufficient generation of 
neutralizing antibody against all three genotypes of the virus. However, interestingly, 
once infected with a strain, patients develop natural immunity and are protected from 
further exposures. Many approaches have been adopted to design an effective vaccine: 
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a) Inactivated vaccine: This conventional vaccine uses generation of neutralizing 
antibodies as the modus operandi for preventing the infection. Studies by Wu et 
al showed the antibodies, stimulated by heat killed and formalin-inactivated 
vaccine, were able to neutralize EV71 infection in neonatal mice on passive 
transfer. A major drawback for this approach is the dependence of vaccine 
immunogenicity on the preservation of the viral three dimensional structure. 
Inactivation reduces the magnitude of the response which in turn can only be 
restored by increasing the dose or providing adjuvant supplementation. These 
steps bring in new challenges in terms of stability and vaccine side effects [42].   
b) Attenuated strain vaccine: Through their primate studies, Minerato Arita and 
associates showed the development of broad spectrum neutralizing antibodies on 
immunization with a 3D polymerase mutated EV71 attenuated strain. While the 
attenuated strain was not fatal to the monkeys, mild neurological symptoms were 
observed in the vaccine inoculated animals. Further attenuation should ideally 
reduce these side effects, but can also potentially cause genetic instability [43]. 
Another concern with this approach is the possible reversion to the wild type 
virulent strain.     
c) Subunit vaccine: This approach tries to circumvent the challenges of reversion to 
wild type by using only a subunit of the viral capsid as the immunogen. Wu and 
colleagues in 2000 provided evidence of successful generation of neutralizing 
antibody response, CD4 T cell proliferation along with significant induction of 
IFNγ and IL-10 in mice immunized with a recombinant VP1 protein. EV71 
typically colonizes the intestine and making it necessary for the vaccine to be 
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administered orally to generate mucosal immunity. This raises concerns about the 
subunit vaccine's capacity to survive this route of administration given that it no 
longer has the structural integrity of the entire capsid [42]. Also, immunogen 
purification at a large scale is not cost effective.  
d) DNA vaccine: As the name suggests, this approach involves intramuscular 
administration of DNA segments which when expressed through the host cell 
machinery produce antigenic proteins that stimulate an immune response. Several 
groups have investigated the success of this strategy, with Wong Siew Tung's 
group and Wen-Hao Wu's group being prominent ones. Vaccines from both the 
groups elicited persistent neutralizing antibodies in mice [44,42]. Additionally, 
this vaccine type is stable, can be produced with simple DNA isolation methods 
and is cost effective. However, the presence of limited epitopes in the vaccine 
often causes the response to be weak and requires boosting. . 
e) Epitope peptide vaccine: Here, peptides that have been designed to specifically 
contain immunogenic epitopes are administered to induce an immune response. 
The selection of peptides also allows for omission of potential side effects. 
Damian Guang Wei Foo and colleagues identified 3 specific amino acid 
sequences in the VP1 protein which elicited T helper cell proliferation along with 
IL-2 and IFNγ production in the immunized mice. They further showed that this 
technique could be used to identify B-cell epitopes [45]. Although there are 
limited data on this front, this approach addresses most of the concerns pertaining 
to vaccine development. 
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f) Virus like particle vaccine: This involves generation of immune responses using 
virus particles that are devoid of their RNA genome but contain all the structural 
proteins and components as the wild type virus. Yu-Chen Hu and others 
demonstrated the spontaneous development of the viral like particles from the P1 
protein and 3CD expression. These particles were shown to be capable of 
inducing Th1 as well as Th2 type immune responses [46]. However, the logistics 
and scale up of these particles need to be determined. [47]. 
Recently the phase three clinical trial of the inactivated alum adjuvant EV71 vaccine was 
concluded in China.  In the trial carried out by Feng-Cai Z and collaborators, study 
participants were given an intramuscular dose of the vaccine on day 0 and then on day 
28. Vaccine efficacy was 90% against EV71-associated HFMD and 80.4% efficacy 
against EV71-associated disease. While serious adverse events were seen only in 1.2% of 
the vaccine administered arm, 71.2% study participants complained of adverse events. 
Although the results are encouraging, the trial failed to address a few crucial points like 
cross reactivity. Also, in light of recent data from a sentinel Shenzhen hospital that 
suggested 80% of the HFMD patients to be children below the age of 5 years [48], the 
lack of vaccine efficacy data in this demographic is conspicuous [14].   
1.7 Treatment 
Despite the tremendous progress in vaccine development and focus on prevention 
strategies, treatment of EV71 infected cases is still crucial for disease control. Many 
research groups have carried out drug discovery studies with a myriad of compounds all 
in a bid to find an effective antiviral against EV71 infection. With the resolution of the 
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virus structure and its life cycle, different stages of the pathogen life cycle are being 
targeted for inhibition. (Figure.4) 
a) Drugs targeting viral attachment and entry: The attachment to host cell surface 
receptors is pivotal for viral invasion and subsequent replication. Two 
functionally important receptors namely SCARB2 receptor and PSGL-1 are 
specifically used by VP1 on the EV71 capsid to attach and invade monocytes, 
dendritic cells, epithelial cells etc. In addition to these, secondary receptors such 
as heparan sulfate, sialylated glycans and annexin II are used by the virus to 
concentrate on the host surface and improve infectivity. Inhibiting this step would 
impede invasion and subsequently disrupt viral replication. Several therapeutic 
compounds have been identified and tested for their antiviral efficacy. Both 
highly sulfated suramin and kappa carrageenan, a sulfated polysaccharide 
derived from seaweed specifically target the VP1 protein in the capsid. It is 
hypothesized that these compounds are able to disturb the structural integrity or 
steric hindrance of the capsid and thus block binding [34,49]. Seiya Yamayoshi 
and co-workers displayed binding inhibition in a dose dependent manner using 
monoclonal antibodies against SCARB2 receptors [30].  
b) Drugs targeting viral uncoating: The successful binding of VP1 to the receptors 
and low pH trigger a series of events in which the capsid undergoes a 
conformational change to yield an A-capsid that is ready to release its genome 
into the host cytoplasm. Inhibition of this conformational change would prevent 
release of the viral genome into the host cells and stall infection. Compounds like 
BPROZ-194 and pleconaril are pocket binders that have been designed to 
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specifically bind to the hydrophobic pocket under the canyon depression. 
However both compounds were found to be ineffective after initial experiments. 
On the one hand, the occurrence of a single point mutation in VP1 enabled the 
virus to overcome the binding specificity of BPROZ-194 [50]; on the other hand, 
pleconaril failed to inhibit the development of cytopathic effect by the 1988 
Taiwan EV71 isolate [51].  
c) Drugs targeting viral RNA translation: EV71 employs cap independent 
translation to initiate protein synthesis. IRES in the viral RNA along with ITAFs 
facilitate translation of the positive sense viral RNA into a single large 
polyprotein. Zhiqiang Wu and colleagues in 2009 identified several small 
interfering RNA (siRNA) against the circulating strains in China [52]. While 
these inhibitors are extremely specific for the amino acid sequence of VP1, they 
are unable to persist in the plasma due to their short half life. Other inhibitory 
nucleotides like phosphodiamidate morpho oligomers (PPMO) inhibit the IRES 
and prevent it from engaging ITAFs for translation. While this strategy recorded a 
6 log10 reduction in poliovirus 1 and human rhinovirus titers in infected cell 
cultures, it is yet to undergo evaluation in the case of EV71 [53].   
d) Drugs targeting viral polyprotein processing: Even though translation results in 
the formation of the polyprotein, functional proteins, required for replication and 
virion assembly, are only available after proteolytic cleavage of the polyprotein. 
This is carried out by two viral proteases, 3C and 2A at specific sites in the 
polyprotein [8]. Additionally, these enzymes have been shown to be important for 
down regulating type 1 IFN production [37]. Thus, inhibition of these critical 
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enzymes can be an effective alternative to the current antiviral therapies.  Nisrine 
Falah's group showed that this is possible by using the peptide LVLQTM to block 
the active site on 2A protease [54]. Another compound that was extensively 
studied for its inhibitory properties was Rupintrivir, a 3C protease inhibitor 
originally designed for human rhinoviruses [55]. However, the drug's P1' group 
could not access the S1 pocket of EV71's 3C protease and thus was rendered 
ineffective against infection [51]. Other inhibitors that have been studied as 3C 
protease inhibitors include fisetin and rutin. These compounds have been shown 
to possess inhibitory activity at 85µM and 100µM respectively [56].  
e) Drugs targeting viral RNA dependent RNA polymerase (RdRp): In order to 
produce infectious progeny, the viral RNA must be used as a template for 
synthesis of a negative strand which then would facilitate the formation of 2 
positive sense strands of RNA. This process is dependent on the VPg protein that 
must be uridylated to VPg-pUpU which serves as the RNA primer. This is another 
opportunity to target a crucial stage in the viral life cycle. In 2004, Shih et al 
identified DTrip-22, a compound that restrained the accumulation of positive and 
negative sense RNA in the cell. However, a single amino acid substitution in the 
3D protein conferred resistance to the drug [57].  
Despite the different strategies and targets available, developing an EV71 specific drug 
has been largely unproductive. Most of the drug candidates, although promising during 
the in vitro phase, have been unsuccessful in replicating their results during scale up and 
subsequent clinical trial phases. This is further compounded by the fact that EV71 has an 
error prone RNA dependent RNA polymerase that has a high mutation rate. While 
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combination therapy could be a promising tactic to counter such virus mutation 
strategies, they need extensive evaluation. These challenges when coupled with the sheer 
magnitude of an epidemic with severe pediatric complications, present a dismal picture of 
healthcare and EV71 therapy worldwide. Furthermore, they gravely underscore the 
pressing need for development of new antiviral drugs specific for EV71.  
Given the biology and the mutation capacity of the virus, targeting a viral protein that is 
conserved through all the genotypes and one which is indispensible for virus survival, 
would theoretically be an ideal approach for developing antiviral drugs. In the case of 
EV71, non-structural proteins like the 3C and 2A proteases are more likely to be 
conserved as they are essential for most of the replication processes which include 
processing of the viral polyprotein, cleavage of precursor proteins to yield other non 
structural proteins like the 3D polymerase [21]. Additionally, their proteolytic activity is 
essential for processing polyprotein and forming infectious virions. Thus, targeting these 
enzymes is an attractive alternative to inhibit viral activity. 
2. Protease inhibitors 
Protease inhibitors have been successfully employed to target several known viral 
pathogens. At present, this approach is being extensively used to retard HIV-1replication. 
Drugs that specifically target the HIV-1 protease are routinely administered in 
combination with nucleoside and non-nucleoside inhibitors as a part of the highly active 
antiretroviral therapy (HAART) to thousands of HIV-1 patients worldwide. This class of 
drugs has been shown to be effective in significantly reducing the viral load and 




2.1 HIV-1 protease inhibitors  
HIV-1 protease inhibitors are peptidomimetic compounds that contain a nonhydrolyzable 
hydroxymethylene core in place of the traditional peptide linkage. Being small in size, 
PIs snuggly sit in the cleft of the HIV-1 protease homodimer and thus block the active 
site. This prevents the enzyme from binding to the HIV-1 polyprotein and thus averts 
cleavage. Rabi SA and colleagues in their recent work on HIV-1 protease inhibitors 
demonstrated that while the HIV-1 protease inhibitors are unable to prevent the budding 
out of immature virions, they are able to affect the subsequent virion entry, reverse 
transcription and post transcriptional steps [22].  
Ample evidence of their efficacy and safety has been gathered over the years through 
population studies and large scale clinical trials. Additionally, being well tolerated with 
minimum side effects, HIV-1 protease inhibitors have dramatically changed the 
landscape of HIV-1 treatment. Currently, there are ten FDA approved protease inhibitors 
namely, Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir,  Lopinavir, 
Nelfinavir, Ritonavir, Saquinavir and Tipranavir [20]. Owing to remarkable success with 
viral inhibition, HIV-1 protease inhibitors continue to be the focus of various studies to 
understand the mechanism involved and their possible application as therapy for other 
viruses. (Figure.5) 
2.1.1 HIV-1 protease inhibitors broad spectrum antiviral activity 
One of the initial studies that hinted at the broad spectrum antiviral activity of HIV-1 PIs 
was by Chan KS and coworkers in 2003. They found that on administering 
lopinavir/ritonavir along with the standard hospital treatment to 75 severe acute 
respiratory syndrome-coronavirus (SARS-CoV) patients, there was an overall significant 
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reduction in the death rate by 2.3% [25] as compared to the controls (p<0.05). 
Furthermore, in the same year of 2003, during the SARS epidemic in Guangzhou, Xiao 
Ping Chen and colleagues reported the distinctive absence of SARS-CoV infection in 19 
HIV-1 infected patients who were being treated with HAART in the same hospital [24]. 
These two studies provided preliminary evidence of HIV-1 protease inhibitors being 
potential antiviral compounds for SARS-CoV. 
 Later, in 2004, Yamamoto and colleagues screened various compounds to identify 
potential anti-SARS drugs. Using the FFM-1 CoV strain of SARS isolate from and 
patient and vero cells, they not only saw inhibition of cytopathic effects in virus infected 
vero cells, but also an inhibition SARS-CoV virion production post treatment [58].  
In 2009, Satoshi Toma's team investigated the effect of nelfinavir on Hepatitis C 
replication. They noted that on infecting the human hepatoma cell line, Huh7 with a 
subgenomic replicon plasmid from HCV-N, an infectious clone of genotype 1b, and 
subsequently treating with nelfinavir resulted in a dose dependent inhibition of 
intracellular viral replication [23].  
More recently, in 2011, Maurizio Federico reported PI-induced inhibition of vesicular 
stomatitis virus and influenza virus replication. It was observed that the PIs saquinavir 
and nelfinavir were able to reduce the viral yields by 4 logs. Furthermore, through the 
experiments, a reduction of 3 logs of influenza virus yield from MDCK-2 cells was noted 
when treated with HIV-1PIs [59]. These data are suggestive of the broader therapeutic 
applications of PIs and the need to explore their potency against other viruses. Based on 
the aforementioned findings and the rationale of targeting conserved proteins of EV71, 
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this thesis was undertaken to investigate the potential protective efficacy of HIV-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
























AIM & OBJECTIVES 
 
Aim: 
To evaluate the protective efficacy of HIV-1 protease inhibitors against Enterovirus 71 
infection in vitro 
 
Objectives: 
i. Screen different HIV-1 protease inhibitors for antiviral activity against EV71 
infection  
ii. Analyze candidate drug for cytotoxicity and effective drug concentration against 
EV71 infection 














MATERIALS & METHODS 
 
1. Cell culture  
1.1 Vero cells 
African green monkey kidney or vero cells, previously procured from American Type 
Culture Collection (ATCC), were stored at -150°C in liquid nitrogen. Standardized 
laboratory protocols for culturing from frozen stocks were followed a few days prior to 
experimentation. Cells were retrieved from cold storage, thawed in a water bath at 37°C , 
immediately washed with growth medium to minimize cell death and seeded into a 
75cm
2
 T-flask. Dulbecco's modified essential medium (DMEM) supplemented with 2mM 
L-glutamine, 10% fetal bovine serum (FBS) and treated with 1% penicillin and 
streptomycin was used as the growth medium. Cells with appropriate volume of growth 
medium were maintained at 37°C and 5% CO2 saturation. 
For splitting and seeding, vero cells were washed with 1X phosphate buffer saline (PBS) 
twice and then treated with 1X 0.5% trypsin-EDTA. Excess trypsin-EDTA was discarded 
followed by incubation of culture flask at 37°C and 5% CO2 saturation for 5 minutes. 
Cells were washed with 1ml DMEM supplemented with 10% FBS and seeded as per 
requirement.   
1.2 HB2 cells 
HB2 cells or human breast epithelial cells immortalized by the introduction of SV40 
genes were obtained from the ATCC and stored at -150°C in liquid nitrogen. 
Standardized laboratory protocols for culturing from frozen stocks were followed a few 
days prior to experimentation. Cells were retrieved from cold storage, thawed in a water 
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bath at 37°C, immediately washed with growth medium to minimize cell death and 
seeded into a 75cm
2
 T-flask. Dulbecco's modified essential medium (DMEM) 
supplemented with 2mM L-glutamine, 10% fetal bovine serum (FBS) and treated with 
1% penicillin and streptomycin was used as the growth medium. Cells with appropriate 
volume of growth medium were maintained at 37°C and 5% CO2 saturation.  
Standardized laboratory protocol was followed for seeding and splitting cells for the 
experiments. 
1.3 U87MG cells 
U87MG or human glioblastoma cells were previously procured from ATCC stored at -
150°C in liquid nitrogen till use. Standardized laboratory protocols for culturing from 
frozen stocks were followed a few days prior to experimentation. Cells were retrieved 
from cold storage, thawed in a water bath at 37°C, immediately washed with growth 
medium to minimize cell death and seeded into a 75cm
2
 T-flask. Dulbecco's modified 
essential medium (DMEM) supplemented with 2mM L-glutamine, 10% fetal bovine 
serum (FBS) and treated with 1% penicillin and streptomycin was used as the growth 
medium. Cells with appropriate volume of growth medium were maintained at 37°C and 
5% CO2 saturation. Standardized laboratory protocol was followed for seeding and 
splitting cells for the experiments.  
1.4 THP-1 cells 
THP-1 cells or human monocyte-like tumor cells, isolated and cultured originally from an 
acute monocytic leukemia patient, were purchased from ATCC and stored in the 
cryofacility. Standardized laboratory protocols for culturing from frozen stocks were 
followed a few days prior to experimentation. Cells were retrieved, thawed in a water 
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bath maintained at 37°C and immediately washed with growth medium. The cell 
inoculum was seeded into a 75cm
2
 T-flask and. Roswell Memorial Park Institute medium 
(RPMI) supplemented with 2mM L-glutamine, 10% fetal bovine serum (FBS) and treated 
with 1% penicillin and streptomycin was used as the growth medium.  Cells were 
maintained at 37°C and 5% CO2 saturation and were cultured at regular intervals.  
1.5 U937 cells 
The U937 cell line procured from the ATCC is an immortalized cell line isolated and 
established from a diffuse histiocytic lymphoma patient. These cells primarily exhibit 
monocytic characteristics making them a suitable in vitro model for antitumor studies. 
The cell inoculum was seeded into a 75cm
2
 T-flask and. RPMI supplemented with 2mM 
L-glutamine, 10% fetal bovine serum (FBS) and treated with 1% penicillin and 
streptomycin was used as the growth medium.  Cells were maintained at 37°C and 5% 
CO2 saturation and were cultured at regular intervals.  
1.6 HeLa cells 
The HeLa cell line is a human cervical cancer cell line that is widely used for in vitro 
analysis of viral infections and testing of antitumor agents. They are essentially adherent 
epithelial cells that were isolated from an adenocarcinoma patient. Standardized 
laboratory protocols for culturing from frozen stocks were followed a few days prior to 
experimentation. DMEM supplemented with 2mM L-glutamine, 10% fetal bovine serum 
(FBS) and treated with 1% penicillin and streptomycin was used as the growth medium. 
Cells with appropriate volume of growth medium were maintained at 37°C and 5% CO2 
saturation. A standardized laboratory protocol was followed for seeding and splitting 
cells for the experiments. 
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1.7 MRC-5 cells 
MRC-5 cells are normal human lung fibroblast cells that were derived from a fetus post 
14 weeks of gestation and are usually used for antiviral efficacy testing. The cell line was 
previously purchased and stored as aliquots in the liquid nitrogen facility. Standardized 
laboratory protocols for culturing from frozen stocks were followed a few days prior to 
experimentation. DMEM supplemented with 2mM L-glutamine, 10% fetal bovine serum 
(FBS) and treated with 1% penicillin and streptomycin was used as the growth medium. 
Cells with appropriate volume of growth medium were maintained at 37°C and 5% CO2 
saturation. Standardized laboratory protocol was followed for seeding and splitting cells 
for the experiments. 
1.8 MDCK-2 cells  
Madin Darby Canine Kidney type 2 cells are a line of epithelial cells derived from the 
distal tubule in the kidney of a dog and are regularly used to test antiviral drugs owing to 
their susceptibility to influenza A and B viruses. These cells were kindly lent to the lab 
by Dr Andy Pekosz and were maintained using DMEM supplemented with 2mM L-
glutamine, 10% fetal bovine serum (FBS) and treated with 1% penicillin and 
streptomycin as the growth medium. For splitting and seeding, MDCK-2 cells were 
washed with 1X phosphate buffer saline (PBS) twice and then washed with 2X 0.25% 
trypsin-EDTA twice. Excess trypsin-EDTA was discarded followed by incubation of the 
culture flask at 37°C and 5% CO2 saturation for 20 minutes. Cells were washed with 1ml 
DMEM supplemented with 10% FBS to stop dissociation and were then seeded as per 




2. Virus growth 
Enterovirus 71 strains H and BrCr were procured from ATCC and stored at -70°C. Prior 
to the experiments, virus vials were retrieved from the cold storage and allowed to thaw 
at 37°C. Both the strains of the virus were propagated in vero cells in DMEM 
supplemented with 2% FBS. Supernatant from cell culture was harvested on development 
of cytopathic effects (CPE).  
3. Drug Titration 
The HIV-1 protease inhibitors Amprenavir, Atazanavir, Indinavir, Lopinavir, Nelfinavir 
and Ritonavir were obtained from the NIH AIDS reagent program. The lyophilized drugs 
were reconstituted according to the purity percentage of the reagent stated by NIH such 
that for a compound of 90% purity, 0.9ml of dimethyl sulfoxide (DMSO) was added to 
achieve the final concentration of 1mg/ml. Similarly, stock concentration of 0.1M was 
prepared, aliquoted and stored at -70°C. Prior to use, they were retrieved, diluted down 
further to desired concentrations using DMSO and DMEM supplemented with 10% FBS. 
Rupintrivir was used as the positive control as it was designed to specifically fit the core 
region of the human rhinovirus 3C protease and has also been shown to act against EV71 
infection. It must be noted here that for the EV71 3C protease, substrate specificity 
determinants are not just limited to its core region (S1' to S4 pocket). They extend to 
region beyond and thereby limit rupintrivir's activity. However, given that this has been 
the only drug to show significant activity, it was used as a control. 
4. Plaque assay 
 Vero cells were seeded in 6 well dishes and incubated overnight to reach 70% 







supplemented with 2% FBS. The different dilutions were added to the designated vero 
cell monolayer containing wells and incubated at 37°C and 5% CO2 saturation for 1 hour. 
Plates were rocked every 15 minutes to facilitate equal coverage of the monolayer. Once 
the unabsorbed virus was removed and monolayers were washed with 1X PBS, an 
overlay of 1% agarose and DMEM was poured over the monolayer in each well. The 
plates were incubated at 37°C and 5% CO2 saturation. At the end of 4 days, cells were 
fixed with formalin, stained with 1% crystal violet dye and then washed under running 
water. Plaques in each well were counted and used to determine the viral titer of the stock 
in plaque forming units/ml (PFU/ml). A similar analysis was used to determine the 
multiplicity of infection (MOI) for the virus.  
5. TCID50 assay  
Vero cells were seeded into a 96 well flat bottom plate with a concentration of 
10
3
cells/100uL of DMEM supplemented with 10% FBS. Cells were added to the wells 
and were incubated overnight to form of a monolayer.  Virus stock was subjected to 




 and was 
added to the monolayers post incubation. The plate was then incubated at 37°C and 5% 
CO2 saturation and examined everyday for CPE. The plate was scored after a period of 3-
4 days where wells with CPE were scored positive and those without were marked 
negative. TCID50 was calculated using the Reed Muench method.  
6. Cell counting  
Vero cells were first trypsinized for 5minutes at 37°C and 5% CO2 saturation, and then 
washed with DMEM supplemented with 10% FBS. The cell mixture was centrifuged at 
1000 rpm for 5 minutes to obtain the cell pellet. The supernatant was discarded and the 
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pellet was resuspended in 1ml of the medium. Cells and 0.1% trypan blue were mixed in 
a 1:1 ratio and loaded onto a hemocytometer for enumeration. Cells that appeared bright, 
devoid of the blue stain and with retention of their round morphology were considered 
live. Cells that appeared blue were considered dead. Cell concentration (cells/ml) was 
determined using the standard formula.  
7. Antiviral Assay 
Vero cells were seeded in 12 well plates at a known concentration of 10
4 
cells/ml per well 
and incubated overnight at 37°C and 5% CO2 saturation to allow monolayer formation. 
Cells in the designated wells were then infected with the virus at a known concentration 
of 0.005 MOI and treated with HIV-1 protease inhibitors at a known concentration of 
10µM. Plates were incubated at 37°C and 5% CO2 saturation and observed for CPE 
development. On the appearance of CPE, the supernatant was aspirated and stored at -
20°C till use. The monolayer was washed and trypsinized to harvest the cells and 
determine cell viability by trypan blue method. All the assays were either performed in 
duplicates or triplicates.  
8. Time of addition assay 
Vero cells were seeded in 12 well plates at a known concentration of 10
4
cells/ml per well 
and incubated overnight at 37°C and 5% CO2 saturation to allow monolayer formation. 
Cells in the -2h wells were pre- treated with 10uM of drug for 2 hours before being 
infected with the virus at a known concentration of 0.005 MOI. Cells in the 0h wells were 
infected with the virus and treated with the drug simultaneously. Cells in the +2h wells 
were initially infected with the virus and then treated with the drug after a 2 hour delay. 
Plates were incubated at 37°C and 5% CO2 saturation and observed for CPE 
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development. On the appearance of CPE, the supernatant was aspirated and stored at -
20°C till use. The monolayer was washed and trypsinized to harvest the cells and 
determine cell viability by trypan blue. All assays were performed in duplicate. 
9. Western Blot analysis 
Supernatant was harvested from the infected cell monolayers for determining the antiviral 
effect of the candidate drug. 60µL of Laemeli sample buffer was added to 180µL of each 
supernatant sample and boiled for 10 minutes to denature the proteins. All samples were 
vortexed thoroughly and 15µL were subjected to electrophoresis using 0.75mm 12% 
sodium dodecyl sulfate polyacrylamide gel. Samples along with the appropriate protein 
ladder were run at 130V for 70 minutes and subsequently the resolved proteins were 
transferred to a polyvinylidene difluoride (PVDF) membrane through a semi-dry transfer 
process. Blots were blocked with 5% BSA solution and then probed with a 1:1000 diluted 
mouse monoclonal antibody against EV71 VP1 protein overnight at 4°C. This was 
followed by washing and labeling with a rabbit derived anti-mouse HRP conjugated 
secondary antibody. Blots were developed using NBT and BCIP solutions.  
10. Density quantitation of blots  
Densitometric analysis of the bands obtained in western blots was carried out using 
ImageJ, a Java based image processing software package developed by the National 
Institutes of Health. Density of the blank wells was taken as baseline and relative to them 
the band density obtained in control and test wells was estimated. Band density was 
measured in optical density (O.D). These values were then converted to percentages 




11. Cytotoxicity assay  
Drug cytotoxicity was determined by the MTS ([3-(4, 5-dimethyl- thiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2- (4-sulfophenyl) - 2H-tetrazolium,   inner   salt])   (Promega,   
Madison, WI USA) method. Vero cells were seeded in a 96 well plate at a known 
concentration of 10
4
cells/100uL per well and incubated overnight at 37°C and 5% CO2 
saturation to allow monolayer formation. Different concentrations of the candidate drug 
were added to the cells and incubated at 37°C and 5% CO2 saturation for 4 days. After 
this, 20uL of the MTS solution was added to each well and incubated at 37°C and 5% 
CO2 saturation for 3 hours. An automated plate reader was used to record the absorbance 
at 490nm. CC50 was determined from the standard absorbance versus dose curve 
generated.  
12. Statistical analysis 
CC50 was estimated using both linear and quadratic regression analysis, and EC50 was 
determined using piece-wise cubic polynomial fitting. Both the values were estimated 
employing Matlab version 2013 (Mathworks, Natick, MA, USA). A t-test was used for 
comparison of VP1 protein yields between two groups. Also, a one-way analysis of 
variance (ANOVA) test was used to compare the VP1 protein yields of the three groups 
in the time of addition assay. For all the tests, a p value = or < 0.05 was considered 
statistically significant. The two statistical tests were carried out using Microsoft Excel 








Rationale: Antiviral activity specific to EV71 was determined by the absence of EV71's 
VP1 protein in the supernatant of cells treated with the drug. This signifies the lack of 
VP1 formation from the viral polyprotein and the subsequent failure of the virus to 
produce virions. Therefore, while using western blots to detect VP1 protein, the lack of 
VP1 protein in the blots is indicative of EV71 inhibition. This is further supported by the 
absence of cytopathic effects among the cells. 
1. Standardization of methods 
Vero cells were passaged 3 to 4 times prior to use for any experiment. A single T-25cm
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flask containing cell culture yielded 3-4 million cells/ml after every passage. Also cell 
viability was calculated and found to be 100%. 
2. Antiviral activity against: EV71 BrCr strain 
2.1. Preliminary screening 
Five HIV-1 protease inhibitors at 10µM each were tested for their antiviral activity 
against EV71 infected vero cells at a concentration of 100TCID50. Of the five drugs 
tested, amprenavir, atazanavir, indinavir, nelfinavir and ritonavir, nelfinavir exhibited the 
highest viral inhibition of 83.43% which was comparable to that observed in the case of 
the positive control drug i.e. rupintrivir. Virus inhibition was seen at a concentration of 
10µM in both the cases. While ritonavir showed marginal inhibition of EV71 at 57.81%, 
indinavir and amprenavir were unable to inhibit the virus and recorded high VP1 yields 




2.2. Dose dependent screening of Nelfinavir 
To further explore the antiviral activity of nelfinavir, vero cells infected with EV71 BrCr 
strain were subjected to drug challenge with tenfold dilutions of nelfinavir from 10µM to 
0.0001 µM. Virus inhibition by nelfinavir was compared to rupintrivir at similar 
dilutions. Although nelfinavir did inhibit virus at 10µM (p=0.0004), it failed to 
completely impede the virus at a lower concentration of 1µM as 58% of VP1 protein was 
detected by the immunoblot. However, this does suggest the existence of antiviral activity 
of the drug at a concentration that is more than 1µM and less than 10 µM.   (Figure.7a & 
b) 
2.2.1. Effective concentration of Nelfinavir  
In order to more accurately determine the effective concentration of nelfinavir, EV71 
infected vero cells were treated with nelfinavir at the following concentrations: 1, 4, 6, 8, 
10, 12 and 14µM. On analyzing the immunoblot obtained from the samples, it was 
confirmed that nelfinavir indeed partially inhibited the virus at 1µM. Also, almost 
complete viral inhibition was seen from 4µM onwards. On calculating the density of the 
VP1 protein obtained with 4µM treatment, it was observed that nelfinavir was able to 
block virus production by 98.4% (p=0.0057). Furthermore, there was 100% inhibition of 
the virus when 6 µM nelfinavir was used (p=0.0050). Additionally, on comparing the 
inhibition levels obtained with 4µM to those obtained with 6µM, it was noted that there 






3. Antiviral activity against EV71 H strain 
3.1. Preliminary screening 
The above mentioned findings prompted testing of HIV-1 protease inhibitors against 
other strains of EV71. The H strain of EV71 was used to infect vero cells at a 
concentration of 100 TCID50 and cells were subsequently treated with 10 µM of 
amprenavir, atazanavir, indinavir, nelfinavir and ritonavir, for investigating possible 
antiviral activity. The VP1 protein detected in cells treated with nelfinavir was the lowest 
out of the six protease inhibitors. Only 16.57% VP1 was recorded from nelfinavir 
treatment, indicative of 83.43% viral inhibition. Among the other protease inhibitors, 
amprenavir displayed minor antiviral activity by blocking 26.1% virus compared to the 
controls. Comparatively, atazanavir, indinavir and ritonavir should no viral inhibition as 
they recorded high yields of VP1 protein in their western blots: 85.8%, 97.35 and 99.3% 
respectively. (Figure.9a & b) 
3.2. Dose dependent screening of Nelfinavir 
In order to precisely resolve the antiviral activity of nelfinavir against EV71 H strain, an 
increasing dose range of nelfinavir was selected and tested with EV71 H strain infected 
vero cells. Virus infected cells were treated with 1, 4, 6, 8, 10, 12 and 14µM of nelfinavir 
and supernatants were analyzed for VP1 yields. While nelfinavir was noted to have 
limited antiviral activity of 86.68% at 1µM (p=0.00001), greater viral inhibition was 
observed with increasing concentrations of nelfinavir. At a concentration of 4µM, 
nelfinavir was found to almost completely inhibit the virus as only 0.24% (p=0.0000001) 
VP1 protein was detected. On increasing the dose by 2µM, complete or 100% inhibition 
of the virus was achieved as no VP1 protein was detected when compared to the negative 
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control (p=0.0000001). Additionally, no significant difference (p=0.3104) was observed 
between the virus inhibition level obtained at 4µM and 6µM. (Figure.10a & b) 
4. Cytotoxicity and effective concentration determination 
The MTS assay was used to examine the cytotoxicity experienced by vero cells exposed 
to increasing concentrations of nelfinavir. In general, a linear dose dependent response 
was observed with cell death being recorded at higher doses of nelfinavir. Using linear 
regression, the dose versus absorbance curve estimated the 50% cytotoxic concentration 
(CC50) of nelfinavir to be 19.97 µM or 20µM approximately. The root mean square error 
(RMSE) for this curve model was 0.1311 suggesting a good fit of the curve to the data. 
Furthermore, to obtain a more precise value of CC50, quadratic regression was carried out 
which revealed a CC50 of 15.65 µM. This model displayed better fit of the curve to the 
data as the RMSE was 0.0666 (Figure.11a).  
The 50% effective concentration (EC50) of nelfinavir against EV71 infection was 
determined by plotting a dose response curve. Piece-wise cubic polynomial fitting was 
used for this scenario as linear and quadratic polynomial fitting produced poor R
2
 and 
RMSE values. Also, the nature of curves did not seem to capture the expected physical 
picture. On plotting the values using this model, the EC50 for nelfinavir was estimated to 
be 1.16 µM with an R
 
denoting good fit of the model. (Figure.11b) 
5. Comparing effect of Nelfinavir on EV71 BrCr and H strain 
On comparing the virus inhibition levels obtained with same doses of nelfinavir, both 





6. Time of addition assay   
The time of addition assay was carried out to investigate the dependence of antiviral 
activity on time of addition of drug. This experiment would provide an initial idea about 
the infection phase dependence of the drug and what would be the ideal phase of 
treatment. Pre treatment was carried out to see if the drug was able to prevent the entry or 
uncoating of the virus and delayed treatment was carried out to ascertain the drug's ability 
to interrupt viral life cycle in an infected cell. Three times points of treatment were 
assessed namely, (i) nelfinavir treatment 2 hours before infection (-2h), (ii) nelfinavir 
treatment concurrently with infection (0h) and (iii) nelfinavir treatment 2 hours after 
infection (+2h). Individually at each time point, nelfinavir treatment resulted in almost 
complete blockade of the virus with 98.88% (p=0.0008), 98.91% (p=0.0008) and 97.74% 
(p=0.0012) inhibition levels for (-2h), (0h) and (+2h) groups respectively. Carrying out 
comparative analysis of the VP1 protein detected at the different time points revealed no 
difference in the degree of inhibition exerted by nelfinavir. Treatment with nelfinavir at 
three different time points yielded consistent levels of VP1 protein and the difference in 
all groups was statistically insignificant (p=0.7736). (Figure.12a & b) 
7. Therapeutic index of nelfinavir:  
Therapeutic index (TI) was used as a measure for the drug's therapeutic potency and was 
determined using the cytotoxicity and effective concentration values of nelfinavir as 
TI50= CC50/EC50. A high TI is indicative of an effective antiviral capacity with minimum 





8. Antiviral Activity against other viruses 
8.1 HAV 
The promising results of nelfinavir's antiviral activity obtained against EV71 infection 
prompted the exploration of the drug's effect on other members of the picornaviridae 
family. Hepatitis A virus (HAV) was cultured in vero cells and maintained in DMEM 
supplemented with 10% FBS.  
Vero cells infected with 100 TCID50 of HAV were then treated with 1, 2, 3, 4, 5, 6, 7, 8, 9 
and 10µM of nelfinavir and cells were analyzed for HAV infection. As HAV antibody 
was unavailable, antiviral effect of HAV was estimated by the absence of CPE in cell 
culture. Cell viability was used to as a measure of the drug's anti- HAV effect.  
On the whole, nelfinavir was noted to have significant variable antiviral activity against 
HAV infection at different concentrations. A comparative analysis of the different levels 
of virus inhibition obtained with different concentrations (1-10µM) of nelfinavir 
displayed significant variation among the groups, suggesting the inhibition levels would 
be dependent on the drug dose (p=0.000000003). In the absence of treatment, HAV 
infection greatly reduced cell viability to 23.13% of the uninfected cells. In contrast to 
this, maximum cell viability was seen in case of cells treated with 4µM nelfinavir, where 
132.43% cell viability was observed. Also, the difference between 4uM treated and 
untreated cells was seen to be significant (p=0.000009). Significant cell viability levels 
were recorded for cells treated with nelfinavir up to 6µM (p=0.0002). However, cell 
viability was lowest at 22.21% when treated with 10µM nelfinavir and cell death was 
observed in this case. Also, on comparing the cell viability recorded at this concentration 
to the negative control, no significant difference was seen (p=0.7516). Additionally, on 
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comparing the cell viability levels obtained with nelfinavir treatment ranging from 1µM 
to 6µM, only a marginal difference was noted suggesting, that nelfinavir had a similar 
antiviral effect (p=0.024) in this dose range. (Figure.13a & b) 
9. Cytotoxicity evaluation with other cell lines 
In order to further examine the cytotoxicity of nelfinavir, possible variation in antiviral 
effect with the cell type and its effects on specific tumors, a small pilot study was carried 
out on a 2 panels of cell lines. Panel 1 consisted of tumor cell lines- HB2, U87MG, 
THP1, U937 and HeLa cells and panel 2 was relatively smaller containing only 2 non-
cancerous cells lines namely MRC-5 and MDCK-2 cells. Both panels were treated with 
1, 2, 4, 8 and 16µM of nelfinavir. A standard concentration of  10
3
cells/100µL was used 
across all the cell lines and high cell viability was used as an indicator of low drug 
cytotoxicity. For the adherent cell type that included HB2, U87MG, MRC5, HeLa and 
MDCK cell lines, cells were monitored for CPE everyday for a period of 4 days. On day 
4, cells were harvested and cell viability was estimated using trypan blue method. For the 
non-adherent cell type that included THP-1 and U937 cell lines, cell viability was 
determined daily for 4 days using trypan blue method.  (Figure 14a. & b.) 
9.1 Panel I 
9.1.1 HB-2 cells 
HB-2 or immortalized luminal epithelial cells were found to be completely tolerant to all 
the above mentioned concentrations of nelfinavir except 16µM. Relative to the untreated 
control cells (blank) only 4.54% viable cells were detected and the difference between 




9.1.2 U87MG cells 
U87MG or human primary glioblastoma cells were noted to be unaffected by almost all 
of the tested nelfinavir concentrations except 16µM (p=0.5579). Compared to the 
untreated well, cells in the 16µM well exhibited CPE and only 28.57% were viable. 
However this difference in viability was not found to be statistically significant 
(p=0.1734).  (Figure 14.d) 
9.1.3 THP-1 cells  
THP-1 cells or leukemic human monocytic cells were treated with the above mentioned 
dose panel of nelfinavir. In contrast to the untreated cells, cells treated with 16 µM 
prominently displayed CPE. While this difference was not statistically significant 
(p=0.2475), a stark numerical difference was noted as only 32% of them were viable 
relative to the untreated cells.  (Figure 14.e.1 & e.2) 
9.1.4 U937 cells  
This immortalized monocytic cell line was treated with progressively increasing 
concentrations of nelfinavir and studied for its effect on cell survival. While cell viability 
remained increased or unchanged up to 8µM (p=0.5431), a sharp fall in live cell count 
was recorded in the 16µM treatment well as only 35.5% of the cells were viable 
(p=0.1554). (Figure 14.f.1 & f.2) 
9.1.5 HeLa cells   
The human cervical cancer cell line was also treated with same range of nelfinavir 
concentrations as stated above and was observed for morphological changes and cell 
death over a period of 4 days. Cells that were treated with a higher dose of nelfinavir i.e. 
16µM were no longer detectable (0%) under the microscope suggesting they had severely 
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diminished in numbers and this reduction in cell viability was found to be statistically 
significant (p=0.0210). (Figure 14.g) 
9.2 Panel II 
9.2.1 MRC-5 cells  
The non-cancerous human lung fibroblast cell line was subjected to nelfinavir treatment 
at different concentrations to assess the cytotoxicity to cells. Cell viability was only 
4.54% in the 16µM treated cells as opposed to the untreated cells that served as the 
control (p=0.0377). However, there was no significant decrease in the cell viability at the 
lower concentrations of the drug (p=0.8492). (Figure 14.h) 
9.2.2 MDCK-2 cells  
MDCK-2, the second cell line in the non-cancerous panel, was primarily composed of 
epithelial cells found in canine kidney. These cells displayed a nelfinavir tolerance 
capacity up to 8µM dosage. However, on treating them with a higher drug concentration 
of 16µM, CPE was noted in addition to a significant reduction in viable cell number 
(p=0.0111). (Figure 14.i) 
An overall comparison of both the cell line panels showed 16µM to be the least tolerated 
dose of nelfinavir as all cell types exhibited major reduction in viability relative to their 
respective untreated controls and no statistically significant variation was found among 
this subset (p=0.2920). (Figure 14.a & b) 
This analysis also revealed a very interesting and unusual trend in both the cell panels. In 
all the cell lines, treatment with nelfinavir at lower concentrations (i.e. up to 6µM) 
resulted in a small boost in the viable cell number to the extent that they were found to be 
more than their respective untreated control cells. In panel I (i.e. HB-2, U87MG, THP-1, 
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U937 & HeLa cells), the increase in cell viability percentage was seen throughout and 
was highly significant in case of HB-2, THP-1 and HeLa cells (p=0.0042, 0.0020, 0.0022 
respectively). In panel II, although cell viability of MRC-5 and MDCK-2 cells did 
quantitatively exceed the viability levels in their corresponding untreated controls, this 






















Enterovirus 71, the etiological agent of Hand, foot and mouth disease, is a major public 
health issue especially for young children in the first five years of life [8]. Most of the 
recent epidemics have been reported from the eastern hemisphere with a large proportion 
of them being from China [61]. Outbreaks of the virus were recorded across the country 
in 2008 with Anhui province being the epicenter with approximately 490,000 cases. More 
recently in 2012, 2,168,737 confirmed cases of HFMD were documented by the Chinese 
Center for Disease Control and Prevention in mainland China [61, 62]. The occurrence of 
the epidemic has also been noted in other countries, such as Thailand, Singapore and 
Vietnam to name a few [5,6,7]. Although mostly self resolving, the virus can cause 
complications and lead to chronic sequelae, such as severe encephalitis, pulmonary 
edema and heart failure [8].  
To date there is no licensed vaccine or drug available as an effective intervention strategy 
with patients being completely dependent on care management for temporary relief from 
symptoms. Given the scale of the epidemic, the severity of the pathophysiology, and the 
lack preventive and treatment strategies, research to develop an effective antiviral drug 
against EV71 infection is deeply warranted. Many drugs, utilizing varying mechanisms, 
have failed in the past to demonstrate efficacy against EV71 infection due to a myriad of 
reasons, including the inability to specifically block VP1 protein and mutations in the 
hydrophobic binding pockets. In this project, we reason that targeting viral enzymes, such 
as 3C or 2A proteases would be more productive because in addition to being 
indispensible for virus replication, these viral proteins are more likely to be conserved in 
all the different subtypes of EV71.  
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One of the biggest challenges of drug development is identification of an active substance 
that has a good safety and bioavailability profile. A strategy that has been successfully 
adopted in the past to treat health problems like rheumatoid arthritis, Cushing syndrome 
and HIV-1/AIDS is drug repositioning [19]. Repositioning allows for accelerated 
investigation of existing drugs, which have previously established safety data, against 
new diseases and health conditions.  
Based on the above mentioned rationale and the success of repositioning, we chose to 
screen various HIV-1 protease inhibitor compounds that have been effectively used in 
HAART for HIV-1 infected individuals, for activity against EV71 infection.   
In this project, we have shown that vero cells infected with EV71 BrCr and H strains can 
be effectively used as an in vitro model to assess the activity of HIV-1 protease 
inhibitors.  Our preliminary screening of five different HIV-1 protease inhibitors revealed 
nelfinavir to have potential antiviral activity against EV71 infection in vitro. This initial 
inspection phase allowed us to identify and focus on a single candidate drug. While no 
studies to date have examined the action of HIV-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
protease inhibitors on EV71 infection, they have been tested against other RNA genome 
based viruses. Norio Yamamoto and colleagues in 2004 investigated the applicability of 
various anti-HIV-1 drugs and found nelfinavir to inhibit SARS associated coronavirus. 
They showed the drug to have strong inhibitory action against viral replication in addition 
to being a deterrent to virus induced cytopathic effects [58].  We obtained similar results 
in our study where nelfinavir was able to impede EV71 infection effectively.  These 
preliminary findings prompted further analysis of the nelfinavir's antiviral activity.  
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To gain a better understanding of nelfinavir’s antiviral activity, tenfold serial dilutions of 
the drug were uniformly challenged with EV71 BrCr of known concentration and 
compared to the antiviral activity of the positive control drug, rupintrivir. It must be noted 
that rupintrivir is a peptidomimetic compound designed to inhibit the 3C protease enzyme 
in human rhinovirus (another enterovirus) and was thus taken as the positive control for 
this study. A declining antiviral activity was detected, with maximum virus inhibition of 
100% recorded with treatment with 10µM. It should be noted here that a partial antiviral 
activity of 58% was detected at 1µM treatment. This was indicative of the existence of 
dose dependent inhibition of EV71 BrCr by nelfinavir. Also when nelfinavir's drug action 
was compared to rupintrivir on a dose by dose basis, it was observed that there was no 
significant difference (p=0.199725) between the two drugs. This suggested that 
nelfinavir's antiviral action was comparable to that exhibited by rupintrivir and thus 
warranted further investigation of its antiviral activity against EV71 infection.   
These experiments hinted at nelfinavir being a potential broad spectrum antiviral drug 
and strengthened our case. As seen with any other drug candidate, the 50% effective 
concentration or EC50 is essential to express and describe the drug's ability to block the 
virus by half. Yamamoto et al determined the EC50 of nelfinavir against SARS-
coronavirus to be 0.024 µM [58]. In contrast, in another study that examined the effect of 
nelfinavir on HCV replication, Toma S et al estimated the EC50 to be 9.88 µM [23]. Our 
study revealed the EC50 of nelfinavir to be 1.1610 µM. In the absence of a clinical trial 
the therapeutic implications of this finding are still undetermined; however, the EC50 in 
our study is very close to the plasma concentration range observed during the clinical use 
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of nelfinavir (i.e. 3.3 to 6.0 µM) against HIV. This is clearly indicative of the fact that the 
effective dose is well within the tolerance range of humans.  
This was further confirmed by the cytotoxicity concentration of nelfinavir required to 
reduce cell viability by 50%. Our study revealed CC50 of nelfinavir to be 15.65µM. These 
findings were however not in accordance with the results obtained by Yamamoto and co 
workers (CC50=2.75 µM) [58]. In another study done to assess the effect of nelfinavir as 
an inhibitor of Kaposi's sarcoma associated herpes virus replication, nelfinavir was not 
cytotoxic at concentrations less than 20µM [63]. The variation seen among the different 
studies could be attributed to the use of different methods to evaluate cytotoxicity. While 
we used the MTS assay to study the cytotoxicity, both the Yamamoto group and Gantt 
group employed the MTT method. 
In addition to these factors, the therapeutic index of nelfinavir was determined to be 13.5 
and this was used as a measure for its therapeutic potency. However, a higher value of 
302.1 therapeutic index or selectivity index was reported by Yamamoto et al when testing 
against SARS-CoV [58]. In another study that tested nelfinavir's therapeutic application 
on vesicular stomatitis virus and influenza virus, therapeutic index values of 22 and 15 
were calculated respectively [59]. This difference in values can be ascribed to the 
variation seen in the EC50 and CC50 for different viral infections tested and their 
corresponding effect on the therapeutic index value.  
The drug action was not restricted to a single strain of EV71. To ascertain that the 
antiviral effect was a pan EV71 phenomenon, all the assays were repeated for vero cells 
infected with EV71 H strain. We observed similar and in some cases higher levels of 
virus inhibition when treated with nelfinavir. Furthermore, statistical analysis revealed no 
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difference in the inhibition levels obtained by nelfinavir action of the BrCr strain and H 
strain of EV71. These data underscore the 'umbrella inhibitory effect' nelfinavir has on 
EV71 infection in vitro. Other studies done on nelfinavir have only recorded its action 
against a single study virus and strain, thereby limiting the scope of their findings. With 
these results our study highlighted the potential broad antiviral property of nelfinavir.  
In addition, one of the objectives of our study was to investigate the timing of nelfinavir 
treatment and its effect on the outcome. It was found that irrespective of when the drug 
was added to the cells, virus inhibition was seen in all the three groups (i.e. -2h, 0h and 
+2h). This observation suggests that nelfinavir may not be specifically acting to inhibit 
entry of the virus per se. Having said that, it also not clear if indeed there is inhibition of 
viral entry. Experiments specifically detecting the inhibition of viral RNA in the cell 
would provide better evidence. Also, the fact that inhibition was seen in the delayed 
treatment group alludes to nelfinavir's possible impediment of the viral life cycle in virus 
infected cells. Again, as mentioned earlier, whether this can be interpreted as an 
inhibition of the polyprotein processing steps or replication remains unclear. This initial 
observation requires further experimental verification to conclusively state nelfinavir's 
role. However, these data do suggest that drug treatment appears to be independent of the 
time of treatment or virus exposure.   
The promising results obtained with the two different strains of EV71 prompted us to ask 
the next logical question of whether nelfinavir would have any action against other 
members of the picornaviridae family. To address this question, vero cells were infected 
with hepatitis A virus and treated with nelfinavir. Also, to reduce the number of potential 
variables and confounders affecting the study, the same cell concentration, drug dose 
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panel and experimental conditions were maintained for the HAV experiment. Emergence 
of CPE in cells was the experimental end point and was indicative of the therapeutic 
failure of the drug. As seen in the case of EV71 infection, HAV infection was inhibited in 
cells treated with nelfinavir. Antiviral effect was seen 2µM onwards with the highest 
being seen at 4 µM (130%). Cells at these concentrations had no change in their 
morphology and lacked CPE completely suggesting a possible anti-HAV effect of the 
drug.  
Although these experimental results highlight the positive therapeutic nature of nelfinavir 
against EV71 and HAV, it is crucial to grasp the importance of this finding in the light of 
the current status of treatment interventions available. While many may argue that these 
infections are self limiting and can be managed with supportive care, in a lot of cases and 
especially those with complications, the lack of therapeutic tools results in delayed 
recovery, prolonged morbidity and in some cases death. In their study on the neurological 
manifestations of EV71 infection, Peter McMinn's team reported the poor effect of 
intravenous immunoglobulin (IVIG) therapy containing neutralizing antibodies to EV71 
[64]. Similar findings were seen in by Huang CC and co workers in 34 patients with 
culture positive EV71 infection [65]. In another study, Luan-Yin Chang and co workers 
noted that although IVIG was given, it failed to inhibit sequelae, progression to 
cardiopulmonary failure and had no appreciable benefit when compared to the untreated 
group [66].  
Similarly, type-I IFN therapy had earlier been proposed as therapeutic option owing to it 
general antiviral properties. However, murine studies later showed type I IFNs to be 
ineffective when administered after the infection [67]. Furthermore, in the clinical setting, 
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the protective effect is marginal [68]. Apart from this, steroids have also been tried as 
therapy for EV71 infections but have been met with little success. In their 2009 EID 
report, Sophie Vallet and colleagues described the rapid deterioration of a 17 month old 
boy who was given symptomatic medication and oral rehydration for EV71 infection. 
Despite, the administration of intravenous corticotherapy along with aerosol and oxygen 
therapy within 12 hours of discharge, the patient was unable to recover and died [69].  
Milrinone, a phosphodiesterase inhibitor that is commonly used in cardiac failure patients 
has also been tested as a candidate drug for the treatment of EV71 infection and 
associated pathology. In the recently concluded randomized milrinone therapy clinical 
trial, Ching-Chuan Liu's group showed that milrinone was able to reduce the EV71 
induced pulmonary edema associated mortality. However, a limitation to this approach is 
the absence of antiviral activity of the drug per se which would greatly restrict its use 
[70].  
While the aforementioned drugs have been tested in human subjects, efficacy testing of 
ribavirin has been restricted to in vitro studies.  Guofeng Zhang's group studied the 
presence of antiviral activity for ribavirin in RD cells. However, the drug displayed a 
very high value of EC50 (89.23 to 178.42 µg/ml) [71]. Although the Zhang group also 
tested pleconaril, a capsid binding drug, and highlighted its anti-EV71 efficacy, Kak-
Shan Shia's study revealed the drug's inability to neutralize CPE induced by the 1998 
Taiwan outbreak strain of EV71 [72].  
In comparison to all these drugs, we found nelfinavir to be suitable drug option for EV71 
infection owing to its low EC50 seen in our study. Additionally, it is able to directly affect 
the virus and cause inhibition, unlike steroids and IVIG. Also, it has been shown to be 
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effective irrespective of the time of administration i.e. before or after infection. 
Moreover, our study was also able to provide preliminary clues about the relationship 
between drug treatment, antiviral activity and time of infection. 
Another, viral infection that usually takes months to resolve if untreated is hepatitis A 
virus. In some cases it may cause fulminant hepatitis and cholestasis. For instance, Nicola 
Coppola's group in 2007 reported a case of acute HAV with severe cholestasis that was 
not resolved by antibiotic treatment and a long course of prednisone [73]. In light of these 
facts and the data generated in our pilot study, we speculate that nelfinavir could be a 
probable anti-HAV drug. Having said that, ours is a preliminary study and this aspect of 
the drug requires further investigation. 
An intriguing aspect of the drug that was observed in the course of this study was the 
effect of nelfinavir on tumor cell lines. Traditionally, nelfinavir was designed to inhibit 
the viral protease enzyme. However, increasing research and the conspicuously low rates 
of HIV associated cancers among patients on HAART, indicated anticancer implications 
for HIV protease inhibitors. In their seminal paper, the Gills' group first demonstrated 
nelfinavir to be an anti-neoplastic agent inducing autophagy, endoplasmic reticulum 
stress and apoptosis both in vitro and in vivo [74]. Out of the six HIV-1 protease 
inhibitors (nelfinavir, saquinavir, ritonavir, indinavir and atazanavir) tested on two non-
small cell lung cancer cell lines, namely A549 and H157, they found nelfinavir to be the 
most potent with mean 50% growth inhibition at the 8µM and 9µM concentrations 
respectively. Furthermore, they tested 60 other tumor cell lines and reported nelfinavir to 
be have a mean cytotoxic concentration of 5.2µM, in addition to being cytotoxic at a 
concentration of ≤10 µM in 14 cell lines [74]. Subsequently in another study by M Kraus 
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and colleagues, nelfinavir was shown to be cytotoxic to myeloma cells namely U266, 
AMO-1, LP-1 and RPMI8226 at the 20µM - 40µM concentration [75].  
Similar findings with respect to nelfinavir cytotoxicity were observed in the present 
study. Five cancerous human cell lines i.e. HB-2, U87MG, THP-1, U937 and HeLa cells 
were used to represent a range of cancers namely breast cancer, glioblastoma, acute 
monocytic leukemia, histiocytic lymphoma and cervical cancer. When these cell lines 
were tested with increasing concentrations of nelfinavir, it was noted that all of them 
were inhibited at concentrations at or above 8µM. Also, there was drastic drop in the cell 
viability at a higher concentration of 16µM of nelfinavir, suggesting that the 50% growth 
inhibition concentration would lie in this range. It should be noted here, that these 
findings are also in accord with another study that evaluated the inhibitory concentration 
of nelfinavir for glioblastoma and is currently undergoing clinical trial. In comparison to 
their inhibitory concentration of 20µM, the current study gives as a more specific range 
of the concentration [76]. A comparable trend was seen in the case of MRC5 cells and 
MDCK cells. 
In addition to these findings, an unusual pattern was recorded in this study. While overall 
the trend of cell viability suggested a progressive decline with increasing concentration of 
the drug, a more careful analysis of the curve revealed an initial increase or boost in the 
cell viability. This significant increase in cell viability was more when compared to the 
cells in the untreated control well and was mostly seen in all cells treated with up to 6µM 
of nelfinavir. Whether this observation could explain the rise in CD4 cell count on 
initiation of HAART in HIV infected patients remains to be investigated.  
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To grasp a better understanding of the findings, it should be noted that the Cmax for 
nelfinavir in HIV patients ranges from 7-9µM [74] and in this study nelfinavir was found 
to most potent between 8-16µM. This combined with the fact that it is surprisingly not 
cytotoxic at lower concentrations leads to us to hypothesize that nelfinavir is a potential 






















In summary, despite being one of the most widely occurring epidemics that lacks 
effective prevention and control tools, EV71 induced hand, foot and mouth disease 
continues to be the proverbial elephant in the room. Through this in vitro study we have 
tried to address the compelling question of effective treatment for EV71 infection. We 
identified nelfinavir, an HIV-1 protease inhibitor as a potential candidate and 
demonstrated it to have high protective efficacy along with low cytotoxicity. The study 
highlighted nelfinavir's ability to significantly inhibit two different strains of EV71 
thereby eliciting a pan-EV71 antiviral activity. Additionally, it shed light on nelfinavir's 
extended antiviral applications to HAV infection and its antitumor effects, thereby 
suggesting it to be a potential broad spectrum drug. The findings of this pilot study 
provide the basic groundwork for more advanced experiments aimed at finding a potent 














There are a few important research questions that remained unanswered at the end of our 
study and would be considered while designing future experiments. Although it was 
beyond the scope of this pilot study, the study was unable to expertly provide a 
mechanistic explanation of nelfinavir's broad spectrum antiviral activity especially in the 
case of EV71 and if its activity was greater than that shown by rupintrivir. The existence 
of structural similarity between the HIV and enterovirus proteases which could account 
for this inhibition or presence of unique protein folding needs to be determined. In order 
to strengthen the proposed model of EV71 inhibition by nelfinavir, the molecular basis of 
the inhibition needs to be better understood. 
 Currently we are in the process of testing nelfinavir's antiviral activity against other 
member viruses of the picornaviridae family including coxsackie A16. Also as it has been 
found to be well tolerated by MDCK cells, we are also testing its possible effect on 
influenza virus in an endeavor to open up treatment options to infectious disease causing 
viruses with a similar premise. Another crucial aspect of the study that requires further 
investigation is the pathophysiology of EV71 infection and how late into the infection 
nelfinavir therapy can be started. Finally, at the pharmacokinetic level, we would like to 
analyze the possibility of generating nelfinavir derivatives and investigate their efficacy 
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Figure.1 :  Phylogenetic analysis of enterovirus 71 VP1 gene sequences 
A neighbor-joining tree constructed with the Kimura-2 parameter as a model for 
nucleotide substitution. The robustness of the tree was determined by bootstrapping, with 
use of 1000 pseudoreplicates. 
 
Source: Solomon, T., Lewthwaite, P., Perera, D., Cardosa, M. J., McMinn, P., & Ooi, M. H. (2010). Virology, 




Figure.2 :  Enterovirus 71 virion structure and genome layout  
 
Human enterovirus 71. (a) Schematic of virion structure. Each protomer in the virus capsid 
contains four structural viral proteins (VP1–VP4). (b) Viral genome layout. All the structural 
proteins are encoded by the P1 region, while P2 and P3 regions encode seven non-structural 
proteins (2A-2C) and (3A-3D). UTR=untranslated region. VPg=virus encoded protein (c) Ribbon 
model representation of a single icosahedron unit formed by the interaction of VP 1,2 and 3 in the 
EV71 capsid (d) Radius-colored surface representation of the EV71 mature particle. The surface 
of the mature virion is colored to represent the distance from the center; blue denotes subunits 
closer to the center and red denotes subunits farthest from the center. 
Source: Solomon, T., Lewthwaite, P., Perera, D., Cardosa, M. J., McMinn, P., & Ooi, M. H. (2010). Virology, 
epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis, 10(11), 778-790. doi: 10.1016/S1473-
3099(10)70194-8;  Wang, X., Peng, W., Ren, J., Hu, Z., Xu, J., Lou, Z., . . . Rao, Z. (2012). A sensor-adaptor 




Figure.3 :  Schematic illustration of EV71 life cycle and antiviral agents  
 
Source: Tan, C. W., Lai, J. K., Sam, I. C., & Chan, Y. F. (2014). Recent developments in antiviral agents against 








Figure.4: List of antivirals against EV-71 infection tested in vitro & in vivo (contd.) 
 
Source: Tan, C. W., Lai, J. K., Sam, I. C., & Chan, Y. F. (2014). Recent developments in antiviral agents against 
enterovirus 71 infection. J Biomed Sci, 21, 14. doi: 10.1186/1423-0127-21-14 
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Figure.5: HIV-1 protease inhibitor drugs  
 

















Figure.6: Preliminary assay of HIV-1 Protease inhibitors with EV71 BrCr strain 
 
(a) EV71 (BrCr) VP1(~37KDa) bands detected by the western blot after treatment with 
HIV-1 protease inhibitors (concentration= 10µM). 
 
 
 (b) EV71 (BrCr) VP1 protein quantified western blot yield obtained after treatment with 





Figure.7: Dose dependent screening of Nelfinavir with EV71 BrCr strain 
 
 
(a) Comparison of EV71 (BrCr) VP1(~37KDa) bands detected by the western blot after 
treatment with rupintrivir and nelfinavir 
 
         
(b) Comparison of EV71 (BrCr) VP1 protein quantified western blot yield obtained after 







Figure.8: Effective concentration of Nelfinavir with EV71 BrCr strain 
 
(a) EV71 (BrCr) VP1 (~37KDa) bands detected by the western blot after treatment with 
nelfinavir at varying concentrations 
 
(b) EV71 (BrCr) VP1 protein quantified western blot yield obtained after treatment with 




Figure.9: Preliminary assay of HIV-1 Protease inhibitors with EV71 H strain 
 
(a) EV71 (H strain) VP1(~37KDa) bands detected by the western blot after treatment 
with HIV-1 protease inhibitors (concentration= 10µM) 
 
 
(b) EV71 (H strain) VP1 protein quantified western blot yield obtained after treatment 





Figure.10: Effective concentration of Nelfinavir with EV71 H strain 
 
(a) EV71 (H strain) VP1 (~37KDa) bands detected by the western blot after treatment 
with nelfinavir at varying concentrations 
 
(b) EV71 (H strain) VP1 protein quantified western blot yield obtained after treatment 




Figure.11: Nelfinavir cytotoxicity and effective concentration determination 
 
(a) EC50 determination using piece-wise cubic polynomial fitting. * denotes the EC50 
estimated from the model.  
 
(b) CC50 determination using linear regression and quadratic regression. * denotes the 
CC50 estimated for each model.  
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Figure.12: Time of addition assay 
 
 
(a) VP1 (~37KDa) bands detected by the western blot after treatment with nelfinavir at 
different times: (-2h) indicates 2 hours pre treatment with drug, (0h) indicates concurrent 
addition of drug and virus and (+2h) indicates 2 hours delayed treatment with drug.  
 
 
(b) VP1 protein quantified western blot yield obtained after treatment with nelfinavir at 






Figure.13: Effective concentration of nelfinavir against hepatitis A virus  
 
 








(b) Total live cells (in millions) counted after treatment of HAV infected cells with 
















Figure.14: Nelfinavir cytotoxicity evaluation of different cell lines 
 














(c) Effect of varing nelfinavir concentration on HB2 cell line and the corresponding cell 
viability trend observed. Black line represents cell viability trend.R
2




(d)  Variation of U87MG cell viability with increasing concentration of nelfinavir. Black 
line represents cell viability trend. R
2




(e.1) Effect of neflinavir concentration on THP1 cell line and the cell viability trend 
observed. R
2
= root mean square error 
 





(f.1) Variation in U937 cell viability with increasing concentration of nelfinavir.  cell 
viablity trend is represented by the black line. R
2
= root mean square error 
 





(g) Effect of neflinavir concentration on HeLa cell line and corresponding the cell 
viability trend observed. R
2
= root mean square error  
 
 
(h) Effect of neflinavir concentration on MRC-5 cell line. Cell viability trend is 
represented by two lines. The red line represents the declining trend predicted using 
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exponential curve fitting. The black line represents the trend predicted using linear curve 
fitting. R
2
= root mean square error 
 
(i) Dose wise effect of neflinavir on MDCK-2 cell line and the cell viability trend 
observed. R
2
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